Close Menu
    Facebook X (Twitter) Instagram
    Friday, November 6
    Top Stories:
    • China’s AI Chipmakers Turn Profitable: Can the Momentum Last?
    • Major Trial Challenges Who Needs Statins
    • Hua Hong Bets Big on Silicon Photonics for AI Boom
    Facebook X (Twitter) Instagram Pinterest Vimeo
    IO Tribune
    • Home
    • AI
    • Tech
      • Gadgets
      • Fashion Tech
    • Crypto
    • Smart Cities
      • IOT
    • Science
      • Space
      • Quantum
    • OPED
    IO Tribune
    Home » Major Trial Challenges Who Needs Statins
    Science

    Major Trial Challenges Who Needs Statins

    Lina Johnson MercilliBy Lina Johnson MercilliNovember 6, 2026No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Top Highlights

    • CorCal compared calcium scans with traditional risk scores for guiding statin recommendations.
    • Scans prompted over three times fewer recommendations, yet both groups had 2.7% cardiovascular events.
    • Scan-guided patients adhered substantially more often to statins: 62%, versus 23% with traditional assessment.
    • However, the trial failed to prove scans were noninferior; larger studies must assess long-term outcomes.

    A Different Lens on Heart Risk

    Doctors often use age, cholesterol, blood pressure and smoking history to estimate who may benefit from statins. A major trial tested another option: a CT scan that detects calcium in artery plaque.

    The study included 5,772 adults without known heart disease or diabetes. After an average of 4.2 years, 2.7% of people in each group experienced a major cardiovascular event, such as a heart attack, stroke or death. Yet the similar rates do not prove that the two approaches work equally well.

    Fewer Recommendations, More Follow-Through

    Calcium scans led to more than three times fewer recommendations to start statins than standard risk scores. Still, among people advised to take the drugs, 62% in the scan-guided group followed through, compared with 23% in the traditional-assessment group.

    Seeing evidence of plaque may make prevention feel more personal. That could help patients weigh a daily medication against a risk they can see. However, the trial did not explain the adherence gap or show that scans improved health outcomes.

    A Promising Question, Not a New Rule

    For people near the threshold for treatment, a scan may offer doctors another piece of information. But the trial had fewer cardiovascular events than expected and did not establish that scan-guided care was no worse than standard assessment.

    That distinction matters. Statins can reduce cardiovascular risk, while unnecessary treatment may bring cost, inconvenience and concerns about side effects. More research is needed to learn whether scans can target treatment more effectively without sacrificing protection. For now, patients should discuss their personal risks and options with a health care professional.

    Expand Your Tech Knowledge

    Explore the future of technology with our detailed insights on Artificial Intelligence.

    Access comprehensive resources on space and science by visiting NASA.

    Sci-BioV1

    Asia Biotech health Innovation Medical medicine Tech VT1
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleAI Companies Want to Buy Your Work Files and Emails
    Next Article China’s AI Chipmakers Turn Profitable: Can the Momentum Last?
    Avatar photo
    Lina Johnson Mercilli
    • Website

    Lina Johnson Marcelli is the editor for IO Tribune, bringing over two decades of experience in journalism to her role. With a BA in Journalism, she is passionate about delivering impactful stories that resonate with readers. Known for her keen editorial vision and leadership, Lina is dedicated to fostering innovative storytelling across the publication. Outside of work, she enjoys exploring new media trends and mentoring aspiring journalists.

    Related Posts

    Tech

    China’s AI Chipmakers Turn Profitable: Can the Momentum Last?

    November 6, 2026
    AI

    AI Companies Want to Buy Your Work Files and Emails

    November 6, 2026
    Science

    The Hidden Recycling Problem with Lightweight Packaging

    November 6, 2026
    Add A Comment

    Comments are closed.

    Must Read

    China’s AI Chipmakers Turn Profitable: Can the Momentum Last?

    November 6, 2026

    Major Trial Challenges Who Needs Statins

    November 6, 2026

    AI Companies Want to Buy Your Work Files and Emails

    November 6, 2026

    The Hidden Recycling Problem with Lightweight Packaging

    November 6, 2026

    Google Find Hub Alerts You When You Leave a Tracker Behind

    November 6, 2026
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    Most Popular

    Revolutionary 15-Minute Hepatitis C Test: A Game Changer!

    December 14, 2025

    Unyielding Spirit: Exploring Megabreccia Mysteries

    September 9, 2025

    Morse Micro Launches High-Power Wi-Fi HaLow Module

    June 2, 2026
    Our Picks

    Quectel Unveils Android 16 Modules for 4G/5G IoT

    August 20, 2026

    Could This Fractal Pattern Propel ETH to $2,500? Insights from an Analyst.

    December 15, 2025

    I Accidentally Uncovered the Galaxy Z Flip 7’s Durability

    July 12, 2025
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    • About Us
    • Contact us
    Copyright © 2025 Iotribune.comAll Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.